ConvaTec

What ConvaTec does

ConvaTec Group plc is a London-headquartered, FTSE 100 global medical products and technologies company focused on chronic-condition management across four care categories: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Its product portfolio is anchored by a proprietary Hydrofiber technology platform with 30 years of heritage and nearly 1.5 billion Aquacel dressings sold worldwide, complemented by emerging platforms including ConvaNiox nitric-oxide wound dressings, ConvaMatrix skin substitutes, InnovaMatrix porcine placental ECM, GentleCath intermittent catheters with FeelClean Technology, Esteem Body ostomy systems, and the Neria Guard infusion set for Parkinson's disease treatment. The company sells more than 900 million consumable units annually across approximately 90 countries.

ConvaTec generates revenue primarily through hardware sales of medical devices and consumables to hospitals, healthcare providers, and individual chronic-care patients. Distribution is multi-channel: an enterprise field sales force calling on hospitals and GPOs (with recent wins including Captis/Vizient and Premier, and extensions with Resource Group), direct-to-patient home services via wholly-owned 180 Medical and Amcare in the United States, and an international distributor network. North America accounts for 55.7% of net sales, and the company holds leading positions across all four chronic-care categories. GPO partnerships (Premier, Captis/Vizient, Resource Group), a long-term AbbVie supply contract for Neria Guard, and a $5 million Lilly Foundation/Partners In Health social-impact collaboration represent notable anchor relationships.

The company operates manufacturing in the UK (Rhymney) and Slovakia (Michalovce), with infusion-set production via Unomedical in Mexico, R&D centers supporting the £500 million UK investment and US expansion, and an executive leadership team led by CEO Jonny Mason (appointed November 2025) and CFO Fiona Ryder. Strategic execution centers on the 'Accelerate' strategy with targets of 6-8% organic revenue growth and mid-20s adjusted operating margins by 2027, supported by 11.7% of sales invested in innovation, a $1B+ R&D facility commitment, and a recent AI-powered SAP S/4HANA digital transformation with LTIMindtree. FY2025 results: $2,439M revenue, 22.3% adjusted operating margin, 16% adjusted EPS growth, and ~100% cash conversion.

Name

ConvaTec

Legal name

Convatec Group plc

Website

https://convatecgroup.com

Company type

Public

Founded year

1978

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

ConvaTec Group plc is a FTSE 100 medical products and technologies company selling chronic-care consumables — wound care, ostomy, continence, and infusion devices — to hospitals, GPOs, and home-care patients across 90 countries, anchored by its proprietary Hydrofiber technology platform.

Ownership category

akta.pro rank

Product category

Chronic Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Services-Home Health Care Services (8082)

akta.pro primary industry

Wound, Ostomy & Continence Care (WOC) at Home (HSABACAE)

akta.pro secondary industry

Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies) (HSABAKAH)

Keywords

• Advanced wound care
• Ostomy care devices
• Continence care catheters
• Infusion care sets
• Chronic care consumables

Headquarters

HQ city

Reading

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Advanced Wound Care Products: Sales of wound care products including Aquacel dressings, ConvaFoam, ConvaNiox, ConvaMatrix, and related advanced wound care solutions. Revenue grew 4.1% organically excluding InnovaMatrix.
2. Ostomy Care Products: Sales of ostomy bags, skin barriers, and accessories including Esteem Body, eakin freeseal, and ESENTA family. Strong growth driven by new patient starts and Esteem Body launch.
3. Continence Care Products: Sales of intermittent catheters and continence products including GentleCath Air for Women, serving patients through home services and healthcare providers. Growth driven by volume expansion in North America.
4. Infusion Care Products: Sales of infusion sets including Neria Guard for Parkinson's disease treatment and other infusion therapies. Double-digit growth from new customers, products and therapies.
5. Home Services: Direct-to-patient supply of catheters and ostomy products through 180 Medical and Amcare home services operations, driving new patient acquisition and customer loyalty.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

ConvaTec develops, manufactures, and distributes single-use medical devices and consumables for the management of chronic conditions across four care categories: Advanced Wound Care (Hydrofiber-based dressings such as Aquacel, ConvaFoam, ConvaNiox, ConvaMatrix, InnovaMatrix), Ostomy Care (Esteem Body, Natura Plus, eakin freeseal, ESENTA accessories), Continence Care (GentleCath intermittent catheters), and Infusion Care (Neria and Neria Guard infusion sets). Products are sold directly to hospitals and clinics, through GPO contracts, and to patients at home via the 180 Medical and Amcare home services businesses.

Product overview

Convatec is a global medical products and technologies company focused on solutions for managing chronic conditions, organized into four care categories: Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. The portfolio includes Hydrofiber-based wound dressings (Aquacel™ Ag+ Extra, ConvaFoam™, ConvaFiber™, ConvaNiox™), skin substitute products (ConvaMatrix™, InnovaMatrix®), ostomy systems (Esteem Body™, Natura Plus™, Mouldable Technology, Stomahesive Technology, eakin freeseal®), continence products (GentleCath Air™ for Women with FeelClean Technology), infusion care devices (Neria Guard™, Neria™), and home services businesses (180 Medical, Amcare). The company has launched or secured approvals for five new wound care products since 2022, underpinned by 30 years of Hydrofiber technology. Products are distributed through multiple channels including direct sales, home services, and group purchasing organizations (GPOs) in approximately 90 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Aquacel: Advanced wound care dressing product line utilizing Hydrofiber technology
• ConvaFoam
• ConvaNiox
• ConvaMatrix
• ConvaFiber
• ConvaVAC
• GentleCath
• Esteem Body
• eakin freeseal
• ESENTA
• Neria Guard
• InnovaMatrix
• Flexi-Seal Air

Products and services

• Aquacel Ag+ Extra

Quantifiable outcome

• Delivered 6.4% organic revenue growth excluding InnovaMatrix in FY25
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Eli Lilly and Company FoundationcoreStrategic or Co-development Partner · 9 June 2026$5 million joint commitment to Partners In Health to support healthcare projects in resource-limited settings focusing on non-communicable diseases and chronic care. Convatec's commitment represents next phase of collaboration with PIH to scale care models and strengthen health systems.
• Eakin HealthcarecoreChannel Partner/ Reseller/ Distributor · 16 March 2026Longstanding exclusive partnership for co-branded eakin freeseal ostomy seal in North America, extending ESENTA family of skin-friendly accessories. The seal is positioned as thinnest and most absorbent on market, available in air and versa variants.
• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 9 February 2026Group Purchasing Organization agreements for supply of enterostomal therapy products, expanding market access for ostomy care portfolio.
• LTIMindtreeminorImplementation/ SI/ Consulting Partner · 17 November 2025Strategic SAP S/4HANA transformation partnership to modernize Convatec's digital infrastructure with AI-powered solutions. Project involves refreshing SAP landscape, streamlining business processes, and enabling AI-powered digital operations across global operations.
• 30 Technology LimitedcoreStrategic or Co-development Partner · 19 April 2023Acquisition of anti-infective nitric oxide technology platform including product assets, R&D capabilities, and planned 2025 product launch for advanced wound care and infection prevention applications. Total commitment up to £176 million in payments based on regulatory approvals and sales milestones.
• AbbViecoreStrategic or Co-development PartnerPartnership for Neria Guard infusion set to deliver apomorphine hydrochloride via subcutaneous infusion for Parkinson's disease treatment in US. Device eliminates need for invasive surgery. Long-term supply contract significantly extended.
• Captis/VizientcoreChannel Partner/ Reseller/ DistributorFirst US Ostomy Group Purchasing Organisation contract win in over 5 years, providing access to Vizient member hospitals and healthcare facilities for ostomy products.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Coloplast: Coloplast is the closest direct peer to Convatec, competing head-to-head across ostomy care, continence care and wound care with comparable product categories, global distribution and a strong chronic-care focus. Both companies lead the global ostomy and continence markets.
• Hollister Incorporated: Hollister is a privately held direct competitor in ostomy and continence care, with overlapping product portfolios, similar hospital and home-delivery channels, and a comparable focus on patient quality of life. It is one of Convatec's primary global rivals in ostomy.
• Smith & Nephew: Smith & Nephew is a direct peer in advanced wound care with comparable products (negative pressure wound therapy, advanced dressings, skin substitutes) and overlapping hospital channel relationships. Convatec's ConvaVAC competes directly against Smith & Nephew's PICO system.
• Mölnlycke Health Care: Mölnlycke is a direct competitor in advanced wound care (Mepilex, Mepitel, Avance NPWT) and surgical solutions, with comparable hospital-channel GTM and chronic-wound focus. It is one of the global leaders against which Convatec's Hydrofiber platform competes.

Broad incumbents

• Baxter International: Baxter is a broad incumbent in infusion care and medical devices with overlapping infusion-set products and chronic-care therapies. Convatec's Neria Guard and broader infusion franchise compete for hospital contracts and chronic-disease therapy partnerships.
• Becton, Dickinson and Company (BD): BD is a broad incumbent medical device manufacturer with overlapping products in infusion sets, continence care, and surgical/wound care applications. Convatec competes against BD for hospital GPO contracts across multiple chronic-care categories.
• Cardinal Health: Cardinal Health is a major medical products distributor and manufacturer with overlapping wound care, ostomy and continence products. As a broad incumbent, it competes with Convatec through its own brands and through wholesale distribution channels.
• McKesson: McKesson is a broad medical distributor and healthcare services company that competes with Convatec through wholesale distribution of competing chronic-care products and home-medical-equipment services in North America.
• Owens & Minor: Owens & Minor is a broad medical-products distributor with wound-care, ostomy and continence products that overlap Convatec's hospital-channel offerings. It competes both as a distributor and increasingly as a manufacturer of private-label wound-care products.

Emerging players

• Solventum (formerly 3M Health Care): Solventum was spun out of 3M in 2024 and includes 3M's legacy Health Care business spanning wound care, surgical supplies and skin-health products. It is an emerging competitor in advanced wound care that overlaps Convatec's Hydrofiber and foam dressing categories.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ConvaTecGroup
• YouTubeyoutube.com/user/ConvatecUSA
• Facebookfacebook.com/ConvaTecOstomyCare
• LinkedInlinkedin.com/company/convatec_2
• Instagraminstagram.com/convatecus

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A11 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ConvaTec